Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 11/20 | 0.64 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | AADAT | Q8N5Z0 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL20549531 | 0.89 | KCNH2 (0.76) | KCNH2SCN5ACYP3A4KDM4EKMT2A | |
| SCHEMBL20549520 | 0.85 | KCNH2 (0.57) | KCNH2SCN5AKDM4EKMT2AAADAT | |
| SCHEMBL20549265 | 0.84 | KCNH2 (0.52) | KCNH2SCN5ACYP3A4KDM4EAADAT | |
| SCHEMBL20549275 | 0.80 | KCNH2 (0.54) | KCNH2SCN5A | |
| SCHEMBL20549410 | 0.79 | KCNH2 (0.83) | KCNH2SCN5ACYP3A4KDM4EKMT2A | |
| SCHEMBL20549966 | 0.78 | KCNH2 (1.00) | KCNH2SCN5ACYP3A4KDM4EKMT2A | |
| SCHEMBL20549509 | 0.78 | KCNH2 (0.55) | KCNH2SCN5ACYP3A4 | |
| SCHEMBL20549463 | 0.76 | KCNH2 (0.78) | KCNH2SCN5ACYP3A4KDM4EKMT2A | |
| Hydrochloric Acid SCHEMBL20549818 | 0.74 | KCNH2 (0.70) | KCNH2SCN5ACYP3A4KDM4EKMT2A | |
| SCHEMBL20549484 | 0.73 | KCNH2 (1.00) | KCNH2SCN5ACYP3A4KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180318311-A1 | TRICYCLIC 2-QUINOLINONES AS ANTIBACTERIALS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2018-11-08 | — | — | US | disclosed |
| WO-2018203302-A1 | TRICYCLIC 2-QUINOLINONES AS ANTIBACTERIALS | NOVARTIS AG (CH) | 2018-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180318311-A1 | TRICYCLIC 2-QUINOLINONES AS ANTIBACTERIALS | TOP1, TOP2A, TOP2B | KCNH2 2920/4885SCN5A 1467/4885CYP3A4 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.